

CITATION REPORT

List of articles citing

Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease

DOI: 10.1182/blood-2009-02-202937
Blood, 2009, 113, 5074-82.

Source: <https://exaly.com/paper-pdf/47273555/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
136	Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease. 2009 , 90, 253-260		43
135	New approaches to allogeneic hematopoietic stem cell transplantation in pediatric cancers. 2009 , 11, 423-30		2
134	Acute graft-versus-host disease: new treatment strategies. 2009 , 16, 427-36		54
133	Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. 2009 , 2009, 124-125		
132	Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study. <i>Blood</i> , 2009 , 114, 4354-60	2.2	39
131	Optimal management of chronic graft-versus-host disease in children. <i>British Journal of Haematology</i> , 2010 , 150, 278-92	4.5	29
130	2009 Publications of the Baylor Health Care System Medical and Scientific Staff. 2010 , 23, 202-219		
129	Pathogenesis and management of graft-versus-host disease. 2010 , 30, 75-101		128
128	Chronic graft-versus-host disease (GVHD) in children. 2010 , 57, 297-322		87
127	Chronic Graft-Versus-Host Disease. 2010 , 189-212		
126	Have we made progress in the management of chronic graft-vs-host disease?. 2010 , 23, 529-35		24
125	Current challenges in chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, S146-51	4.7	34
124	Glucocorticoid-refractory acute graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 1504-18	4.7	49
123	Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 1611-28	4.7	180
122	Allogeneic hematopoietic cell transplantation: the state of the art. 2010 , 3, 285-99		116
121	Notch and inflammatory T-cell response: new developments and challenges. 2011 , 3, 1353-66		14
120	Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1-17	4.7	260

119	Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 124-32	4.7	24
118	Treatment of chronic graft-versus-host disease: Past, present and future. 2011 , 46, 153-63		65
117	A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission. <i>Blood</i> , 2011 , 117, 2113-20	2.2	44
116	Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2011 , 118, 456-63	2.2	69
115	A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFR α antibodies. <i>Blood</i> , 2011 , 118, 4070-8	2.2	36
114	Graft-vs-host disease following allogeneic hematopoietic cell transplantation. 2011 , 18, 268-76		42
113	German-Austrian-Swiss Consensus Conference on clinical practice in chronic graft-versus-host disease (GVHD): guidance for supportive therapy of chronic cutaneous and musculoskeletal GVHD. 2011 , 165, 18-29		31
112	[Graft-versus-host disease (GvHD) - an update. Part 2: prognosis and therapy of GvHD]. 2011 , 62, 229-37; quiz 238-9		5
111	Use of mycophenolate mofetil in patients received allogeneic hematopoietic stem cell transplantation in Japan. 2011 , 93, 523-531		15
110	Biomarkers in chronic graft-versus-host disease. 2011 , 4, 329-42		17
109	Treatment of chronic graft-versus-host disease in 2011. 2011 , 18, 414-20		61
108	Current world literature. 2011 , 18, 474-83		
107	[Chronic graft versus host disease (GvHD): causes, manifestation, diagnosis and treatment option]. 2012 , 137, 2166-70		
106	Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients. 2012 ,		1
105	Section 5: Extracorporeal Photopheresis in Chronic Graft-versus-Host Disease. 2012 , 97-134		
104	cGVHD of skin: simple tools, great advances. <i>Blood</i> , 2012 , 120, 2537-8	2.2	
103	Keep up the heat on IL-1. <i>Blood</i> , 2012 , 120, 2538-9	2.2	10
102	Graft-versus-host disease: part II. Management of cutaneous graft-versus-host disease. 2012 , 66, 535.e1-16; quiz 551-2		68

101	Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group study. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 84-91	4.7	44
100	Mesenchymal stromal cells: a new tool against graft-versus-host disease?. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 822-40	4.7	81
99	Cutaneous graft-versus-host disease--clinical considerations and management. 2012 , 43, 101-15		14
98	Are we making progress in GVHD prophylaxis and treatment?. 2012 , 2012, 251-264		35
97	Immune modulation of inflammatory conditions: regulatory T cells for treatment of GvHD. 2012 , 53, 200-12		19
96	Diagnosis and management of chronic graft-versus-host disease. <i>British Journal of Haematology</i> , 2012 , 158, 46-61	4.5	121
95	Ocular graft-versus-host disease: a review. 2013 , 58, 233-51		134
94	Treatment options for graft-versus-host disease. 2013 , 1, 731-743		1
93	Buka's Emergencies in Dermatology. 2013 ,		
92	Efficacy of photopheresis extracorporeal procedure as single treatment for severe chronic GVHD: a case report. 2013 , 49, 205-7		
91	More than skin deep? Emerging therapies for chronic cutaneous GVHD. <i>Bone Marrow Transplantation</i> , 2013 , 48, 323-37	4.4	17
90	Special Care of Blood and Marrow Stem Transplant Patients. 2013 , 1321-1345		
89	Chronic GVHD: Where are we? Where do we want to be? Will immunomodulatory drugs help?. <i>Bone Marrow Transplantation</i> , 2013 , 48, 203-9	4.4	27
88	Treatment and management of graft-versus-host disease: improving response and survival. <i>Therapeutic Advances in Hematology</i> , 2013 , 4, 366-78	5.7	93
87	Novel immunosuppression compounds and experimental therapies for chronic graft-versus-host disease. 2013 , 130, 34-43		6
86	Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. <i>Blood</i> , 2013 , 121, 2340-6	2.2	43
85	[The 40th scientific meeting: perspectives of internal medicine; present situation and future extension of organ transplantation in Japan; 8. Hematopoietic stem cell transplantation]. 2013 , 102, 585-91		
84	Diagnosis and treatment of graft-versus-host disease. 311-329		1

83	Calcineurin inhibitors in bronchiolitis obliterans syndrome following stem cell transplantation. 2014 , 43, 221-32		5
82	Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. <i>Blood</i> , 2014 , 124, 1363-71	2.2	52
81	Mycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft-vs.-host disease in adult patients in Japan. 2014 , 28, 980-9		14
80	Graft-versus-host disease: why have we not made more progress?. 2014 , 21, 141-7		32
79	Thinking out of the box--new approaches to controlling GVHD. 2014 , 9, 73-84		5
78	Hematopoietic Cell Transplantation in Children with Cancer. <i>Pediatric Oncology</i> , 2014 ,	0.5	2
77	Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients. 2014 , CD009898		1
76	Current issues in chronic graft-versus-host disease. <i>Blood</i> , 2014 , 124, 374-84	2.2	263
75	A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1737-43	4.7	37
74	FFS: an end(point) to our problems in chronic GVHD trials?. <i>Blood</i> , 2014 , 124, 1216-7	2.2	
73	How we treat chronic graft-versus-host disease. <i>Blood</i> , 2015 , 125, 606-15	2.2	185
72	Mycophenolate mofetil for treatment of steroid-refractory acute graft-versus-host disease after pediatric hematopoietic stem cell transplantation. 2015 , 19, 652-8		13
71	Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients. <i>The Cochrane Library</i> , 2015 , CD009898	5.3	3
70	Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1074-82	4.7	11
69	National Institutes of Health State of the Science Symposium in Therapeutic Apheresis: scientific opportunities in extracorporeal photopheresis. 2015 , 29, 62-70		25
68	Prophylactic and therapeutic treatment of graft-versus-host disease in Japan. 2015 , 101, 467-86		20
67	State-of-the-art acute and chronic GVHD treatment. 2015 , 101, 452-66		47
66	Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1576-82	4.7	16

65	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1343-59	4.7	69
64	Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantation. 2015 , 4, 113-126		12
63	Extracorporeal Photopheresis for Second-Line Treatment of Chronic Graft-versus-Host Diseases: Results from a Health Technology Assessment in Italy. 2015 , 18, 457-66		21
62	Graft-versus-host disease management. 2016 , 117, 388-96		4
61	Acute and chronic Graft-versus-host disease after hematopoietic stem cell transplantation. 2016 , 62 Suppl 3, 44-50		15
60	Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease. <i>Blood</i> , 2016 , 127, 160-6	2.2	35
59	Chronic Graft-versus-Host Disease [Clinical Manifestations and Therapy. 2016 , 1020-1039		1
58	DLL4 dendritic cells: Key regulators of Notch Signaling in effector T cell responses. 2016 , 113, 449-457		11
57	Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. 2016 , 17, 164-173		199
56	Bronchiolitis obliterans syndrome in adults after allogeneic stem cell transplantation-pathophysiology, diagnostics and treatment. 2017 , 13, 553-569		13
55	Dermal and Subcutaneous Chronic Graft-Versus-Host Disease. 2017 , 93-103		
54	Diagnosis, Staging, and Treatment of Chronic Graft-Versus-Host Disease. 2017 , 125-138		
53	Mechanistic approaches for the prevention and treatment of chronic GVHD. <i>Blood</i> , 2017 , 129, 22-29	2.2	68
52	A Canine Model of Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 420-427	4.7	9
51	Atlas of Graft-versus-Host Disease. 2017 ,		1
50	Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study. <i>Blood</i> , 2017 , 130, 2186-2195	2.2	17
49	Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. <i>Blood</i> , 2017 , 130, 2243-2250	2.2	220
48	Long-Term Follow-Up Program and Chronic Graft-versus-Host Disease. <i>Journal of Hematopoietic Cell Transplantation</i> , 2017 , 6, 84-97	0.1	1

47	Skin Diseases in the Immunosuppressed. 2018 ,		1
46	Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2018 , 53, 826-831	4-4	55
45	Graft-versus-host Disease-free, Relapse-free Survival After HLA-identical Sibling Peripheral Blood Stem Cell Transplantation With Tacrolimus-based Graft-versus-host Disease Prophylaxis in Japanese Patients. 2018 , 50, 241-245		1
44	Real-life Report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Bone Marrow Transplantation</i> , 2018 , 53, 58-63	4-4	4
43	A phase II/III randomized, multicenter trial of prednisone/sirolimus prednisone/sirolimus/calcineurin inhibitor for the treatment of chronic graft--host disease: BMT CTN 0801. 2018 , 103, 1915-1924		21
42	Chronic graft-versus-host disease: Current management paradigm and future perspectives. 2019 , 25, 931-948		14
41	The use of ibrutinib before and after allogeneic stem cell transplantation. 2019 , 7, 171-180		0
40	Review of Graft-Versus-Host Disease. 2019 , 37, 569-582		41
39	Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1805-1814	4-4	16
38	Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1450-1455	4-7	6
37	Disability related to chronic graft --host disease after alternative donor hematopoietic cell transplantation. 2019 , 104, 835-843		12
36	Safety and efficacy of rituximab-based first line treatment of chronic GVHD. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1218-1226	4-4	5
35	Hydrogen in Patients With Corticosteroid-Refractory/Dependent Chronic Graft-Versus-Host-Disease: A Single-Arm, Multicenter, Open-Label, Phase 2 Trial. <i>Frontiers in Immunology</i> , 2020 , 11, 598359	8.4	1
34	Adverse events in second- and third-line treatments for acute and chronic graft--host disease: systematic review. <i>Therapeutic Advances in Hematology</i> , 2020 , 11, 2040620720977039	5-7	6
33	Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2020 , 95, 1170	7-1	1
32	Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Haematology</i> , 2020 , 7, e100-e111	14.6	32
31	Chronic Graft-Versus-Host Disease. 2021 , 453-476		
30	Salivary ZG16B Expression Loss Marks Onset of Oral Chronic Graft-Versus-Host Disease and Exocrine Gland Dysfunction. <i>SSRN Electronic Journal</i> ,		1

29	Skin chronic GVHD. 2021 , 140-165		
28	Open-Label, Multicenter Phase II Study of Combination Therapy of Imatinib Mesylate and Mycophenolate Mofetil in Pediatric Patients with Steroid-Refractory Sclerotic/Fibrotic Type Chronic Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 925.e1-925.e7		1
27	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 729-737		5
26	Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival. <i>Blood Advances</i> , 2021 , 5, 4549-4559	7.8	1
25	Graft Versus Host Disease: Management of Acute and Chronic Disease. <i>Organ and Tissue Transplantation</i> , 2021 , 365-393	0	
24	Evolving Therapeutic Options for Chronic Graft-versus-Host Disease. <i>Pharmacotherapy</i> , 2020 , 40, 756-773	7.8	8
23	Skin Signs of Other Systemic Diseases. 2011 , 562-579		2
22	Ixazomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Phase II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1612-1619	4.7	6
21	The treatment of chronic graft-versus-host disease: consensus recommendations of experts from Germany, Austria, and Switzerland. <i>Deutsches Arzteblatt International</i> , 2011 , 108, 732-40	2.5	29
20	Phase 2 multicenter trial of ofatumumab and prednisone as initial therapy of chronic graft-vs-host disease. <i>Blood Advances</i> , 2021 ,	7.8	0
19	The clinical landscape of chronic graft-versus-host disease management in 2021. <i>British Journal of Haematology</i> , 2021 ,	4.5	1
18	Advances in Allogeneic Hematopoietic Cell Transplantation: Progress in Transplantation Technology and Disease-Specific Outcomes. 367-383		
17	Management of Chronic Graft-versus-Host Disease 2012. <i>Journal of Hematopoietic Cell Transplantation</i> , 2012 , 1, 37-51	0.1	1
16	Graft-Versus-Host Disease. 2013 , 103-131		
15	Immunosuppressive Agents and Monitoring in Long-Term Survivors. 314-320		
14	Graft Versus Host Disease: From Basics to the Clinic. <i>Pediatric Oncology</i> , 2014 , 57-75	0.5	
13	Special Care of Blood and Marrow Hematopoietic Cell Transplant Recipient. 2018 , 1211-1245		
12	Skin Diseases Associated with Stem Cell Transplantation. 2018 , 117-137		

11	Graft Versus Host Disease: Management of Acute and Chronic Disease. <i>Organ and Tissue Transplantation</i> , 2021 , 1-30	0	
10	Salivary ZG16B expression loss follows exocrine gland dysfunction related to oral chronic graft-versus-host disease.. <i>IScience</i> , 2022 , 25, 103592	6.1	2
9	Management of Chronic Graft-vs.-Host Disease in Children and Adolescents With ALL: Present Status and Model for a Personalised Management Plan.. <i>Frontiers in Pediatrics</i> , 2022 , 10, 808103	3.4	1
8	Skin Signs of Other Systemic Diseases. 2016 , 573-591.e6		2
7	Low-intensity immunosuppressive therapy for chronic graft-versus-host disease. <i>Transplantation and Cellular Therapy</i> , 2022 ,		0
6	Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in children and adolescents. <i>The Cochrane Library</i> , 2022 , 2022,	5.2	
5	High response rate and corticosteroid sparing with arsenic trioxide-based first-line therapy in cGvHD after allo-HSCT. <i>Transplantation and Cellular Therapy</i> , 2022 ,		
4	First-line steroid-free systemic treatment of acute and chronic graft-versus-host disease after novel prophylaxis regimens.		0
3	Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.		1
2	Chronic graft-versus-host-disease treatment in Brazil: analyses of failure-free survival. 2023 ,		0
1	Novel Approaches to the Treatment of Chronic Graft-Versus-Host Disease. 2023 , 41, 1820-1824		0